Home › Gliosarcoma
Gliosarcoma clinical trials recruiting in the U.S.
11 studies for Gliosarcoma are recruiting participants at sites across the United States.
Cities with the most studies
By state
Recently updated studies
MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT03896568ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07089641A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma
RecruitingPhase 1
Ages 19 and older · All sexes · Updated Sep 14, 2026 · NCT05698524Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06934889Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM
RecruitingPhase 1
Ages 12 and older · All sexes · Updated Sep 4, 2026 · NCT04991870HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
RecruitingPhase 1
36 Months – 22 Years · All sexes · Updated Sep 4, 2026 · NCT03911388GI-102 Alone or With Pembrolizumab Before Surgery for Treatment of Recurrent or Progressive IDH Wildtype Glioblastoma and IDH Mutated Grade 4 Astrocytoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Apr 8, 2026 · NCT07301268Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue
RecruitingObservational study
Ages 18 and older · All sexes · Updated Feb 4, 2026 · NCT05756985Study of Pembrolizumab and M032 (NSC 733972)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Jan 22, 2026 · NCT05084430Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Jan 12, 2026 · NCT05465954Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Dec 18, 2025 · NCT04541082From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.